BioWorld

July 14, 2003

View Archived Issues

Indevus Prices $60M In Notes For Overactive Bladder Therapy

Read More

Clot-Busting Drugs Urged By Cardiology College Denied Many Heart-Attack Patients By Doctors

Read More

Proposed Public Offering From Vicuron Highlights Funding Rush

Read More

Other News To Note

Read More

Appointments And Announcements

Read More

CV Therapeutics Regains Full Ranexa Rights From Innovex

Promising Phase III data plus a respectable bank account prompted CV Therapeutics Inc. to renegotiate with partner Innovex Inc. for a return of all rights associated with the chronic angina candidate Ranexa. (BioWorld Today) Read More